Ocrelizumab: simple and flexible therapy at every stage of life

Special report | With kind support from: Roche Pharma AG, Grenzach-Wyhlen

MS therapy during pregnancy and breastfeeding Ocrelizumab: simple and flexible therapy at every stage of life

Thanks to recent changes to the approval of ocrelizumab, women with multiple sclerosis (MS) now have access to a proven, highly effective and safe treatment during family planning and breastfeeding. Contraception is only required for four months after the last dose of ocrelizumab, meaning that a change in therapy is no longer necessary if the patient urgently wishes to conceive [1, 2]. Treatment with the anti-CD20 antibody can be resumed shortly after birth and continued during breastfeeding. Ocrelizumab is therefore a suitable entry-level therapy, especially for young women with MS.